Richard is a UK native and brings a strong connection to the biotech, government and academic communities within London, the UK and throughout Europe. Richard most recently served as Chief Executive Officer of XO1 Ltd, which was acquired through a Johnson & Johnson Innovation-facilitated deal in March of this year.
Prior to his role at XO1-Limited, Richard was Head of Strategy and Business Development at specialty pharmaceutical company BTG Plc, where he devised the strategy for BTG to become a profitable interventional medicine/medical device-focused company, and led its execution through the acquisition of commercial-stage businesses worth over $730m (Biocompatibles, TheraSphere, Ekos Corp). Richard also served in senior management positions for Advent Venture Partners LLC, where he was an interim CEO for several portfolio companies, and at Cambridge Antibody Technology Plc (CAT) where he led business development.
"In my previous role as CEO of XO1, I had the pleasure of getting to know Johnson & Johnson Innovation, and Janssen, very well during the acquisition process and subsequent integration of XO1," said Richard. "What impressed me so much was how Johnson & Johnson has created a really dynamic environment where entrepreneurial people can make great things happen, and quickly, even though they are part of one of the largest companies in the world."
In collaboration with their internal partners at JJDC, R&D, business development, and other global innovation centres, Richard and the London Innovation team will work to continue to identify promising early-stage healthcare solutions in Europe in pharmaceuticals, medical devices and consumer healthcare. Richard assumes the role from predecessor Patrick Verheyen who was recently appointed as Head, Janssen Business Development.
Richard lives near Cambridge, UK. He is married to Angela, who trained as a family doctor, and they have three children. In his spare time he loves running, skiing, is a pilot, and a member of the British Army Reserve. With a true entrepreneurial spirit, a team-focused approach and genuine expertise in value creation through unique collaborations, Richard's appointment signifies a truly exciting milestone for the London Innovation Centre.
Richard will play a crucial role in working with the London IC Team to identify and develop outstanding science and transformative medicines, devices and consumer products. Richard joins the team after successfully working with Johnson & Johnson Innovation as a collaborator under his capacity as the Chief Executive Officer of XO1-Limited which was acquired by Johnson & Johnson earlier this year.